Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 6/20 | 0.46 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31278246 | 0.93 | EGFR (0.49) | GSK3BEGFRMKNK2MKNK1 | |
| SCHEMBL22585743 | 0.93 | EGFR (0.49) | GSK3BEGFRMKNK2MKNK1 | |
| SCHEMBL17822343 | 0.88 | GSK3B (0.49) | GSK3BEGFRMKNK2MKNK1CDK2 | |
| SCHEMBL30883818 | 0.88 | GSK3B (0.49) | GSK3BEGFRMKNK2MKNK1CDK2 | |
| SCHEMBL19532488 | 0.87 | MKNK2 (0.54) | GSK3BMKNK2MKNK1CDK2DYRK1B | |
| SCHEMBL17542604 | 0.84 | MKNK2 (0.53) | GSK3BMKNK2MKNK1CDK2DYRK1B | |
| SCHEMBL19103337 | 0.81 | GSK3B (0.43) | GSK3BEGFRMKNK2MKNK1CDK2 | |
| SCHEMBL19337064 | 0.81 | GSK3B (0.43) | GSK3BEGFRMKNK2MKNK1CDK2 | |
| SCHEMBL19337147 | 0.81 | GSK3B (0.43) | GSK3BMKNK2MKNK1CDK2DYRK1B | |
| SCHEMBL29419125 | 0.80 | MKNK1 (0.50) | EGFRMKNK2MKNK1CDK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | GSK3B 2196/4885EGFR 1/4885ASH1L 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.